

AI-Powered Blood Test To Outsmart Multi-cancer

Make Cancer
Screening
Convenient and
Effective With a
Single Blood Draw

10 Cancer
groups

75 Cancer
subtypes¹

01 AI-
powered
platform

**SPOT-MAS 10 has been
granted U.S. FDA
Breakthrough Device
Designation*.**

(*) Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization. SPOT-MAS 10 remains subject to future FDA review.



Advanced Technology:
Uses cutting-edge DNA sequencing
and AI technologies to screen for
presence of cancer DNA in your
blood (circulating tumor DNA).

99.92%

Accuracy in confirming
the absence of cancer when the
result was negative, based on a
study involving 9,024 people².

(1) Gene Solutions Multi-omics dataset on cancer subtypes (Accessed Sep 2025)
(2) Nguyen, et. al. (2025) Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Med 23, 90. <https://doi.org/10.1186/s12916-025-03929-y>

Why is cancer screening important?

3,000

new cases each day in South-East Asia.

>70%

of cancers in low-income and middle-income Asian countries are **diagnosed in late stage**³.

A majority of the public still believes that a cancer diagnosis inevitably leads to death. However, this perception is often due to **late-stage detection** rather than a lack of progress in treatment³.

The sooner cancer is detected, **the better** treatment outcomes.

(3) Sankaranarayanan et al, 2014. Managing the changing burden of cancer in Asia. BMC Med 12, 3

Advantages of ctDNA technology



Convenience

One single blood draw during a healthcare visit.



High accuracy

High specificity limits false positive and unnecessary work-up.



Assurance

Capability to test for cancers that do not have recommended screenings to improve early detection opportunities.

SPOT-MAS 10 outperforms biochemical markers^{2, 4}:

7–12X higher sensitivity

10–14X higher positive predictive value (PPV)

(4) Sekiguchi, M., & Matsuda, T. (2020). Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening. Scientific Reports, 10(1), 18202–18202. <https://doi.org/10.1038/s41598-020-75319-8>

What is SPOT-MAS™ test?




SPOT-MAS is a non-invasive, multi-cancer early detection (MCED) test that detects tumor DNA (ctDNA) circulating in the blood. This test incorporates next-generation sequencing (NGS) and AI technologies to analyze the multi-omics features of ctDNA, enabling early detection for the most common and aggressive cancers from a single tube of blood^{1,2}.



Only requires a blood draw tube



Next-Generation Sequencing



Multimodal AI

What to do with the results?



Negative:

No ctDNA signal detected

ctDNA was not detected at the time SPOT-MAS test is conducted. This test provides a snapshot of the blood at the time of collection and does not predict for future cancer risks.

Next step

Continue with the SPOT-MAS test annually or other screens as recommended by your doctor. Do not ignore cancer signs or symptoms if they occur, as this could lead to a delayed diagnosis.



Positive:

ctDNA signal detected

ctDNA signal associated with tumor cells was detected in the blood. The result may include 1–2 predictions of the origins of tumor in the body where the cancer may be found.


Next step

As the SPOT-MAS test is a screening test, a confirmatory imaging test is required to confirm if cancer is truly present. Your doctor will advise you on the required following tests.

Who is SPOT-MAS for?

Adults > 40 years old.

The incidence of cancer has increased since 1990. Older persons are at higher risk for cancer⁵.



Cancer incidence by age in Asia between 1990 and 2019 (5)

(5) Sharma et al, 2024. The Lancet Regional Health - Southeast Asia 21,100333.

Adults aged <40 years old with high risks for cancer.

- **Heavy smoking:** People who have a 20 pack-year history of smoking⁶
- **Heavy drinking:** People who drink 15 cans of beer a week (for men) or 08 cans of beer a week (for women)⁷
- **Hereditary risks:** Those who have had tested positive for inherited cancer genes such as BRCA1, BRCA2, TP53⁸
- **Liver diseases:** People who have Hepatitis B or C⁹
- **Familial history:** People whose family members had been diagnosed with cancer¹⁰

(6) Chen et al, 2021 American Journal of Otolaryngology 42, 102915. (7) Connor et al, 2017. Addiction 112, 222–228. (8) Garber et al, 2005. JCO 23, 276–292. (9) Petruzzello et al, 2018. TOVJ 12, 26–32. (10) Brewer et al, 2017. Breast Cancer Res Treat 165, 193–200.

Gene Solutions Genomics Pte Ltd

📍 Tower C, Tai Seng Exchange 5 Tai Seng Avenue, #02-54 Singapore 536671

✉ infosg@genesolutions.com 🌐 www.genesolutions.com

Contact us for more available information



